DrugBiological
Utomilumab clinical trials
Also written PF-05082566 and PF 5082566.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 5
M.D. Anderson Cancer Center (4) · Pfizer (3) · Adrienne G. Waks (1) · Kite, A Gilead Company (1)
Often tested with
Tested in the same studies.
Ivuxolimab (2) · Avelumab (1) · Cetuximab (1) · Irinotecan (1) · Aldesleukin (1) · CD8-Positive T-Lymphocyte (1) · Pembrolizumab (1) · Axicabtagene ciloleucel (1)
Studies
Open first, then newest update. How each study uses utomilumab is read from its arms, and is right about nine times in ten.
Testing it · 9
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT03217747Written as Utomilumab
- The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerActive, not recruitingPhase 2Adrienne G. WaksNCT03414658Written as Utomilumab
- Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT03290937Written as Utomilumab
- T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian CancerCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03318900Written as Utomilumab
- Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedPhase 1Kite, A Gilead CompanyNCT03704298Written as Utomilumab
- Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT03258008Written as Utomilumab
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedPhase 1PfizerNCT02315066Written as PF-04518600 plus PF-05082566
- A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid TumorsTerminatedPhase 1PfizerNCT02444793Written as PF-05082566
- A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)CompletedPhase 1PfizerNCT02179918Written as PF-05082566
Given in every arm · 8 — utomilumab is usual care beside what is tested
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as Utomilumab
- Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaCompletedPhase 1City of Hope Medical CenterNCT03440567Written as Utomilumab
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingPhase 2Laura Huppert, MD, BANCT03971409Written as Utomilumab
- Rituximab + Immunotherapy in Follicular LymphomaTerminatedPhase 1Dana-Farber Cancer InstituteNCT03636503Written as Utomilumab
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)TerminatedPhase 1/2PfizerNCT02554812Written as Utomilumab
- 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerCompletedPhase 1George W. Sledge Jr.NCT03364348Written as Utomilumab
- Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedPhase 3PfizerNCT02951156Written as Utomilumab
- A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedPhase 1PfizerNCT01307267Written as PF-05082566
Codes
What other systems call utomilumab · ClinicalTrials.gg INT006203
- MeSH (NLM) C577122utomilumabOne source NLM
- UNII (FDA) 6YY8O697VFUTOMILUMABConfirmed FDA, NLM
- NCI Thesaurus C116619UtomilumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C577122 | utomilumab | One source NLM |
| UNII (FDA) | 6YY8O697VF | UTOMILUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C116619 | Utomilumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.